Published in Br J Pharmacol on February 01, 2002
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology (2010) 0.97
Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat. Br J Pharmacol (2006) 0.89
NSAIDs: the emperor's new dogma? Gut (2003) 0.82
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther (1949) 13.89
CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT. Br J Pharmacol Chemother (1963) 6.99
Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A (1992) 5.21
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell (1995) 4.17
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1993) 4.05
Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem (1992) 2.97
Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins (1980) 2.78
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71
NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins (1994) 2.60
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology (1998) 2.46
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 2.43
Towards a better aspirin. Nature (1994) 2.20
In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest (1992) 2.04
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest (1996) 1.98
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther (1999) 1.63
Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol (1982) 1.59
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J (1991) 1.54
Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol (1999) 1.54
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol (1993) 1.52
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res (1996) 1.27
Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol (1988) 1.15
Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res (1998) 1.09
The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol (2000) 1.09
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol (2001) 1.03
Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1. J Biol Chem (1996) 0.96
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol (1985) 0.93
Do human platelets express COX-2? Prostaglandins Leukot Essent Fatty Acids (2001) 0.89
Anti-inflammatory and analgesic effects of a novel pyrazole derivative, FR140423. Eur J Pharmacol (1999) 0.84
Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. J Pharmacol Exp Ther (1992) 0.82
Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation. Biochem Pharmacol (1987) 0.81
The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol (1993) 0.80
Adjuvant-induced arthritis in rats. I. Temporal relationship of physiological, biochemical, and hematological parameters. Proc Soc Exp Biol Med (1971) 0.79
Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Exp Anim (1997) 0.78
Anti-inflammatory activity of a novel selective cyclooxygenase-2 inhibitor, FR140423, on type II collagen-induced arthritis in Lewis rats. Prostaglandins Other Lipid Mediat (2001) 0.78
Anti-inflammatory effect of FR140423, a novel selective cyclo-oxygenase-2 inhibitor, in rat adjuvant arthritis without gastrointestinal side effects. J Pharm Pharmacol (2000) 0.76
2-Buten-4-olide (2-B4O) inhibits type II collagen-induced arthritis in Lewis rats. Int J Immunopharmacol (1993) 0.76
A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med (2013) 1.01
Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol (2003) 0.86
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator. J Cereb Blood Flow Metab (2005) 0.86
The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. Acta Crystallogr D Biol Crystallogr (2002) 0.85
Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res (2003) 0.82
Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. Br J Pharmacol (2003) 0.81
FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur J Pharmacol (2002) 0.81
Neuroprotective effect of tacrolimus (FK506) on ischemic brain damage following permanent focal cerebral ischemia in the rat. Brain Res Mol Brain Res (2004) 0.80
Ultrafast all optical switching by use of pulse trapping across zero-dispersion wavelength. Opt Express (2003) 0.79
Pulse trapping by ultrashort soliton pulses in optical fibers across zero-dispersion wavelength. Opt Lett (2002) 0.79
Serum insulinlike growth factor-I in biliary atresia. J Pediatr Surg (2003) 0.79
Characteristics of pulse trapping by ultrashort soliton pulse in optical fibers across zerodispersion wavelength. Opt Express (2002) 0.78
Effects of FK317, a novel anti-cancer agent, on survival of mice bearing B16BL6 melanoma and Lewis lung carcinoma. Cancer Lett (2002) 0.77
Trapped pulse generation by femtosecond soliton pulse in birefringent optical fibers. Opt Express (2002) 0.77
A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J Cereb Blood Flow Metab (2002) 0.76
Flatly broadened, wideband and low noise supercontinuum generation in highly nonlinear hybrid fiber. Opt Express (2004) 0.76
Effect of systemic FR140423, a new analgesic compound, in a rat model of postoperative pain: contribution of delta-opioid receptors. Neurosci Lett (2003) 0.75
Ultrafast all optical switching using pulse trapping in birefringent fibers. Opt Express (2005) 0.75
FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats. Brain Res (2002) 0.75